Bahl & Gaynor’s Omnicell OMCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
– Sell
-27,122
Closed -$2.33M – 359
2019
Q2
$2.33M Sell
27,122
-15,343
-36% -$1.25M 0.02% 215
2019
Q1
$3.43M Buy
42,465
+1,043
+3% +$78.1K 0.03% 160
2018
Q4
$2.54M Sell
41,422
-3,186
-7% -$216K 0.03% 178
2018
Q3
$3.21M Buy
44,608
+1,045
+2% +$65.8K 0.04% 166
2018
Q2
$2.29M Sell
43,563
-7,749
-15% -$364K 0.02% 201
2018
Q1
$2.23M Sell
51,312
-14,353
-22% -$660K 0.02% 201
2017
Q4
$3.19M Buy
65,665
+825
+1% +$41.6K 0.03% 162
2017
Q3
$3.31M Buy
64,840
+10,295
+19% +$493K 0.04% 146
2017
Q2
$2.35M Buy
54,545
+4,400
+9% +$183K 0.03% 173
2017
Q1
$2.04M Buy
50,145
+5,490
+12% +$202K 0.02% 183
2016
Q4
$1.51M Buy
44,655
+6,615
+17% +$228K 0.02% 202
2016
Q3
$1.46M Buy
38,040
+3,430
+10% +$128K 0.02% 196
2016
Q2
$1.18M Buy
34,610
+2,510
+8% +$78.3K 0.02% 211
2016
Q1
$894K Buy
+32,100
New +$882K 0.01% 240

Other funds holding OMCL

Bahl & Gaynor's OMCL Position: Q3 2019 in Review

Bahl & Gaynor sold out of Omnicell (OMCL) in Q3 2019, closing a stake of 27,122 shares — an estimated $2.33M sold.

Bahl & Gaynor first reported a position in OMCL in Q1 2016 and held it in 14 quarters. The position peaked at $3.43M in Q1 2019. 279 funds tracked by Wall St. Rank hold OMCL as of Q3 2019.

  • Bahl & Gaynor reported no remaining Omnicell position as of Q3 2019 after selling out during the quarter.
  • Bahl & Gaynor sold 27,122 Omnicell shares in Q3 2019, an estimated $2.33M.
  • Bahl & Gaynor first reported a position in Omnicell in Q1 2016 and held it in 14 quarters.
  • Bahl & Gaynor's Omnicell position peaked at $3.43M in Q1 2019.
  • 279 funds tracked by Wall St. Rank held Omnicell as of Q3 2019.

Based on Bahl & Gaynor's 13F filing for Q3 2019, filed 14 Nov 2019.